IP Library Granted Patent US 8,367,121
Granted Patent B2
US 8,367,121 · App. 12/658,307 · Granted Feb 5, 2013

Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease

Inventors: Elizabeth Anne Mazzio (Tallahassee, FL); Karam F Soliman (Tallahassee, FL)
Assignee: Florida A & M University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,367,121
App. No.
12/658,307
Granted
Feb 5, 2013
Kind
B2
Abstract

This invention describes a comprehensive nutraceutical designed to antagonize major mitigating factors to the degenerative process associated with Parkinson's disease. The formulation is comprised of a primary base of pyruvate, succinate, α-Ketoglutarate and/or oxaloacetate, niacin/NADH, fruit extracts, anthocyanins, further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The nutraceutical contains all natural substances that should mitigate many of the neurodegenerative processes known to be associated with PD. Mechanisms addressed are to prevent the loss of ATP/by 1-methyl-4-phenylpyridinium rotenone, scavenge hydrogen peroxide/O 2 . − , augment antioxidant enzymes, prevent dopamine (DA) oxidation to DA-quinone via inhibition of COX, PLA 2 , LOX, xanthine oxidase, tyrosinase, prevent hyperhomocysteinemia, antagonize PARP-1 apoptosis, increase blood flow, glucose and oxygen delivery to the brain, potentiate mitochondrial function, antagonize glia iNOS and MAO or its products, chelate redox-active iron, inhibit heme oxygenase-1, inhibit alpha-synuclein aggregation, augment ATP storage, mediate anti-inflammatory effects via inhibition of PDE, MAPK p38/c-Jun NH2-terminal kinase/PGE2, antagonize excitotoxicity and downregulate N-methyltransferase, all of which contribute toward PD pathology.

Claims (22)

1. A composition useful for the treatment of Parkinson's disease comprising a therapeutically effective amount of a composition comprising:

alpha-ketoglutarate;

succinic acid;

pyruvate;

vitamin B6;

lysine;

biochanin A, wherein said biochanin A is optionally derived from alfalfa, soybeans, or red clover;

diosmin, wherein said diosmin is optionally derived from hyssop or rosemary;

butein, wherein said butein is optionally derived from Rhus verniciflua or faba bean;

naringin, wherein said naringin is optionally derived from orange;

strawberry component selected from strawberry powder, strawberry extract, strawberry concentrate, or strawberry juice;

bilberry component selected from bilberry powder, bilberry extract, bilberry concentrate, or bilberry juice;

chromium;

zinc;

Vitamin B3;

Magnesium;

NADH;

quercetin, wherein said quercetin is optionally derived from Marshmallow or St. John's Wort; and

a pharmaceutically acceptable carrier.

2. The composition of claim 1 further comprising one or more ingredient selected from the group consisting of luteolin, apigenin, ascorbate, N-acetyl-L-cysteine, glutathione, beta-carotene, L-carnitine, riboflavin, coenzyme Q10, thiamin, lipoic acid, pantothenic acid, biotin, creatine, phosphorus, acacetin, Scutellaria baicalensis , caffeic acid, chlorogenic acid, robinetin, fisetin, gallic acid, hyperoside, Filipendula ulmaria , isorhamnetin, pycnogenol, pyrogallol, mulberry, vanillic acid, kaempferol, clove, cinnamon, myrrh, ferulic acid, cysteine, methionine, morin, phytic acid, quercetin glucosides, sage, oregano, rutin, silymarin, silybin, sesamol, aurantinidin, cyanidin, delphinidin, europinidin, luteolinidin, pelargonidin, malvidin, peonidin, petunidin, rosinidin, rosmarinic acid, cinnamic acid, omega 3 fatty acid, gromwell root, aloin, sanggenon, scutellarein, sophoraflavone G, sophorcarpidine, tetrahydroxychalcone, wogonin, chrysin, coumarin, cystamine, daphnetin, esculetin, fraxetin, galangin, isoliquiritin, licuraside, licochalcone, ginkgetin, ginkolide, histidine, hydroxychalcone, methylchalcone, hypolatein, isoginkgetin, kenusanone A, kuraridin, kurarinone, ochnaflavone, psoralidin, resorcinol, manganese, selenium, tocopherol, turmeric, amentoflavone, biopterin, cirsimarin, daidzein, phloretin, caffeine, xanthosine, berberine, cytochrome C, histidine, taurine, potassium, glycine, vitamin B12, folic acid, serine, betaine, vitamin A, vitamin D, vitamin E, vitamin K, thymoquinone, EGCG, resveratrol, apple, pear, blueberry, grape seed extract, cherry, elderberry, chokeberry, carrot, cranberry, apricot, acai, and raspberry.

3. The composition of claim 1 wherein said pharmaceutically acceptable carrier is selected from the group consisting of cellulose, silica, water, saline, starches, sugars, flavorings, gels, lipids, waxes, paraffin, glycerols, oils, proteins, talc, glycols, electrolyte solutions, alcohols, gums, fillers, binders, cellulose, magnesium stearate, emulsifiers, humectants, preservatives, buffers, colorants, emollients, foaming agents, sweeteners, thickeners, surfactants, additives, solvents, lubricants, and combinations thereof.

4. The composition of claim 1 wherein said composition is in a form selected from the group consisting of food, drink, solid, liquid, powder, paste, gel, tablet, granule, foam, pack, ointment, aerosol, solvent, tablet, diluent, capsule, pill, liposome, syrup, solution, suppository, emulsion, suspension, dispersion, bolus, electuary, and paste.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 8, 2015
From: FLORIDA AGRICULTURAL AND MECHANICAL UNIV
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035853/0464 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2012
From: MAZZIO, ELIZABETH; SOLIMAN, KARAM
To: FLORIDA A & M UNIVERSITY
Reel/Frame 029592/0117 →
Continuity (4)
Continuation In Part 12220810 · Jul 29, 2008
Continuation In Part 11438746 · May 22, 2006
Provisional Application 60739980 · Nov 23, 2005
Related Publication 20100150895A1 · Jun 17, 2010